Mitsubishi Tanabe Pharma
Osaka, Japan· Est.
Japanese pharmaceutical company developing innovative treatments for immunology, neuroscience, and metabolic disorders.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Japanese pharmaceutical company developing innovative treatments for immunology, neuroscience, and metabolic disorders.
ImmunologyNeuroscienceMetabolic
Technology Platform
Traditional pharmaceutical research and development focused on small molecules and biologics for immunology, neuroscience, and metabolic disorders.
Opportunities
Growing obesity treatment market presents significant expansion potential, while their established neurology franchise (including ALS treatments) provides stable revenue foundation.
Risk Factors
Intense competition in immunology and metabolic markets from larger pharmaceutical companies, pipeline dependency on key late-stage assets like MT-7117.
Competitive Landscape
Faces competition from global pharma giants in immunology (AbbVie, Johnson & Johnson) and metabolic disorders (Novo Nordisk, Eli Lilly), while differentiating through specialized focus on certain neurological and autoimmune conditions.